CRISPR/Vertex gene editing drug cleared for beta-thalassemia
ipopba Vertex Pharmaceuticals (NASDAQ:VRTX) announced Tuesday that the U.S. FDA approved its groundbreaking gene editing therapy, Casgevy, developed with CRISPR Therapeutics (NASDAQ:CRSP) for those aged 12 years and older with…
